Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers
Abstract Background PD-1/PD-L1 blockade plays a crucial role in cancer immunotherapy. Exploration of new technologies to further enhance the efficacy of PD-1/PD-L1 blockade is therefore of potential medical importance. Nanotherapeutics can accumulate in tumor tissues due to enhanced permeability and...
Main Authors: | Qiping Jiang, Fengjiao Yao, Yacong An, Xialian Lai, Xundou Li, Zhen Yu, Xian-Da Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Cancer Nanotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12645-023-00239-x |
Similar Items
-
Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles
by: Xialian Lai, et al.
Published: (2023-03-01) -
Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo
by: Yacong An, et al.
Published: (2022-02-01) -
Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
by: Junjun Fu, et al.
Published: (2023-03-01) -
A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
by: Wei-Yun Lai, et al.
Published: (2016-01-01) -
Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo
by: Ting Li, et al.
Published: (2021-02-01)